Clinical Research Directory

Inclusion Criteria: * Signed informed consent form. * Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years. * CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes. * Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy. * ECOG performance status of 0-1 and no worsening within 2 weeks before the first dose. * Life expectancy ≥ 12 weeks. * Men or women should be using adequate contraceptive measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study. * Females must have evidence of non-childbearing potential. Exclusion Criteria: * CML-CP patients who have acquired CCyR and have not lost it. * Patients with CML-CP who have progressed to AP or blast phase(BP.) * Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood. * Patients with CML-AP who have progressed to BP. * Previous treatment with a BCR-ABL1 TKI allosteric inhibitor . * Impaired cardiac function including any one of the following: * Resting corrected QT interval (QTc) \> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF). * Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG. * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, * Left ventricular ejection fraction (LVEF) ≤ 50%. * Myocardial infarction occurred within 6 months of the first scheduled dose of study drug.; * Congestive heart failure occurred within 6 months of the first scheduled dose of study drug.; * Uncontrollable angina. * History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis * Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes). * Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption. * Severe infection within 4 weeks prior to the first scheduled dose of study drug * Inadequate other organ function. * History of other malignancies. * History of hypersensitivity to any active or inactive ingredient of HS-10382 and flumatinib. * History of neuropathy or mental disorders, including epilepsy and dementia. * Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements